Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Regeneron Pharmaceuticals Inc. buy The Goldman Sachs Group, Inc.

Regeneron Pharmaceuticals Inc.
Start price
€500.00
14.04.25 / 50%
Target price
€805.31
14.04.26
Performance (%)
32.17%
Price
€658.20
12.01.26
Summary
This prediction is currently active. The BUY prediction by The_Goldman_Sachs_Gr for Regeneron Pharmaceuticals Inc. has seen massive gains of 32.17%. Dividends of €2.64 are taken into consideration when calculating the performance. This prediction currently runs until 14.04.26. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this prediction

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

Performance without dividends (%)
Name 1w 1m
Regeneron Pharmaceuticals Inc. 1.137% 1.137%
iShares Core DAX® 2.331% 5.140%
iShares Nasdaq 100 2.077% 2.956%
iShares Nikkei 225® 2.759% 7.214%
iShares S&P 500 1.613% 2.893%

Comments by The_Goldman_Sachs_Gr for this prediction

In the thread Regeneron Pharmaceuticals Inc. diskutieren
Prediction Buy
Perf. (%) 32.17%
Target price 805.309
Change
Ends at 14.04.26

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $1,019.00 to $917.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat

The Goldman Sachs Group, Inc. 
0
Report Share
14.04.25

Stopped prediction by The_Goldman_Sachs_Gr for Regeneron Pharmaceuticals Inc.

buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€524.00
30.04.25
€707.12
30.04.26
26.11%
12.01.26

The Goldman Sachs Group, Inc. 
30.04.25 50%